David I. Sandoval Sells 4,466 Shares of MaxCyte, Inc. (NASDAQ:MXCT) Stock

MaxCyte, Inc. (NASDAQ:MXCT) General Counsel David I. Sandoval sold 4,466 shares of the business’s stock in a transaction on Monday, January 13th. The shares were sold at an average price of $4.54, for a total value of $20,275.64. Following the completion of the sale, the general counsel now owns 41,447 shares in the company, valued at approximately $188,169.38. The trade was a 9.73 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

MaxCyte Stock Performance

Shares of MXCT opened at $4.64 on Wednesday. MaxCyte, Inc. has a fifty-two week low of $3.16 and a fifty-two week high of $5.32. The business has a 50-day moving average of $3.94 and a 200 day moving average of $4.03. The firm has a market cap of $490.50 million, a P/E ratio of -13.65 and a beta of 1.29.

MaxCyte (NASDAQ:MXCT) last posted its earnings results on Wednesday, November 6th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.13) by $0.02. The firm had revenue of $8.16 million during the quarter, compared to the consensus estimate of $7.50 million. MaxCyte had a negative net margin of 78.36% and a negative return on equity of 16.00%. During the same quarter last year, the company earned ($0.11) earnings per share. As a group, research analysts predict that MaxCyte, Inc. will post -0.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On MaxCyte

Hedge funds and other institutional investors have recently bought and sold shares of the business. Intech Investment Management LLC purchased a new position in shares of MaxCyte in the third quarter valued at $51,000. China Universal Asset Management Co. Ltd. lifted its holdings in MaxCyte by 64.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 20,212 shares of the company’s stock worth $79,000 after purchasing an additional 7,930 shares in the last quarter. Verition Fund Management LLC boosted its stake in MaxCyte by 39.5% in the 3rd quarter. Verition Fund Management LLC now owns 21,335 shares of the company’s stock worth $83,000 after purchasing an additional 6,045 shares during the period. Creative Planning grew its holdings in MaxCyte by 33.6% during the 3rd quarter. Creative Planning now owns 28,652 shares of the company’s stock valued at $111,000 after buying an additional 7,212 shares in the last quarter. Finally, SG Americas Securities LLC increased its position in shares of MaxCyte by 84.5% during the third quarter. SG Americas Securities LLC now owns 37,969 shares of the company’s stock valued at $148,000 after buying an additional 17,385 shares during the period. Institutional investors own 68.81% of the company’s stock.

MaxCyte Company Profile

MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.